For instance, allo‐HSCT could overcome the adverse effect of high RUNX1 expression in our MDS cohort, suggesting that patients with higher RUNX1 expression receive allo‐HSCT if eligible. Here, RUNX1 is linked to myelodysplastic syndrome.